Emergent BioSolutions (EBS) Curent Deferred Tax Liability (2013 - 2014)
Emergent BioSolutions (EBS) posted quarterly Curent Deferred Tax Liability of $88000.0 for Q3 2014, little changed quarter-over-quarter from $88000.0 in Q2 2014.
Emergent BioSolutions (EBS) Curent Deferred Tax Liability (2013 - 2014) Analysis & Trends
Emergent BioSolutions' Curent Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $88000.0 for Q3 2014.
- In Q3 2014, Curent Deferred Tax Liability changed N/A year-over-year to $88000.0; the TTM figure through Sep 2014 stood at $88000.0 (changed N/A YoY), while the FY2013 annual figure was $88000.0, changed N/A from the prior year.
- Curent Deferred Tax Liability for Q3 2014 stood at $88000.0, roughly flat from $88000.0 in the prior quarter.
- The five-year high for Curent Deferred Tax Liability was $88000.0 in Q4 2013, with the low at $88000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 88,000.00 |
| Sep 30, 2014 | 88,000.00 |
| Jun 30, 2014 | 88,000.00 |
| Jun 30, 2014 | 88,000.00 |
| Mar 31, 2014 | 88,000.00 |
| Mar 31, 2014 | 88,000.00 |
| Dec 31, 2013 | 88,000.00 |
| Dec 31, 2013 | 88,000.00 |